ICON Public Limited Company - Asset Resilience Ratio

Latest as of December 2024: 0.00%

ICON Public Limited Company (IJF) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of ICON Public Limited Company for a breakdown of total debt and financial obligations.

Liquid Assets

€0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

€16.88 Billion
≈ $19.73 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how ICON Public Limited Company's Asset Resilience Ratio has changed over time. See IJF book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ICON Public Limited Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ICON Public Limited Company (IJF) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €0.00 0%
Total Liquid Assets €0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: ICON Public Limited Company maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

ICON Public Limited Company Industry Peers by Asset Resilience Ratio

Compare ICON Public Limited Company's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Eurofins-Cerep SA
PA:ALECR
Diagnostics & Research 6.56%
Inoviq Ltd
AU:IIQ
Diagnostics & Research 56.29%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Imagion Biosystems Ltd
AU:IBX
Diagnostics & Research 150.16%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Annual Asset Resilience Ratio for ICON Public Limited Company (2016–2024)

The table below shows the annual Asset Resilience Ratio data for ICON Public Limited Company.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.00% €0.00
≈ $0.00
€16.88 Billion
≈ $19.73 Billion
--
2023-12-31 0.01% €1.95 Million
≈ $2.28 Million
€16.99 Billion
≈ $19.86 Billion
+0.00pp
2022-12-31 0.01% €1.71 Million
≈ $2.00 Million
€17.26 Billion
≈ $20.17 Billion
+0.00pp
2021-12-31 0.01% €1.71 Million
≈ $2.00 Million
€17.39 Billion
≈ $20.33 Billion
-0.04pp
2020-12-31 0.05% €1.73 Million
≈ $2.02 Million
€3.44 Billion
≈ $4.02 Billion
-1.66pp
2019-12-31 1.71% €49.63 Million
≈ $58.02 Million
€2.91 Billion
≈ $3.40 Billion
-0.84pp
2018-12-31 2.54% €59.91 Million
≈ $70.04 Million
€2.35 Billion
≈ $2.75 Billion
-1.07pp
2017-12-31 3.61% €77.59 Million
≈ $90.71 Million
€2.15 Billion
≈ $2.51 Billion
-0.11pp
2016-12-31 3.73% €68.05 Million
≈ $79.55 Million
€1.83 Billion
≈ $2.13 Billion
--
pp = percentage points

About ICON Public Limited Company

F:IJF Germany Diagnostics & Research
Market Cap
$8.69 Billion
€7.43 Billion EUR
Market Cap Rank
#2477 Global
#505 in Germany
Share Price
€97.36
Change (1 day)
+12.89%
52-Week Range
€72.94 - €170.30
All Time High
€314.40
About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more